Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma

BACKGROUND: Immunotherapies that target immune-checkpoint molecules such PD-1 have helped to achieve durable responses in melanoma treatment. However, 25% of melanoma patients who showed objective responses to PD-1 blockade develop resistance and suffer from disease progression and ultimately death,...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Inflamm Regen
Main Authors: Han, Nanumi, Baghdadi, Muhammad, Ishikawa, Kozo, Endo, Hiraku, Kobayashi, Takuto, Wada, Haruka, Imafuku, Keisuke, Hata, Hiroo, Seino, Ken-ichiro
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2018
Assuntos:
Case Report
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5836392/
https://ncbi.nlm.nih.gov/pubmed/29515691
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41232-018-0060-2
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares